Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Authors:
- José A. RianchoJRJosé A. Riancho
- José L. HernándezJosé L. Hernández
- Carmen González-VelaCGCarmen González-Vela
- Ana E. López-SundhALAna E. López-Sundh
- Marcos A. González-LopezMGMarcos A. González-Lopez
- Francisco Gomez de la FuenteFFFrancisco Gomez de la Fuente
- Remedios QuirceRQRemedios Quirce
- Eli L. DiamondEDEli L. Diamond
Open Access
- 23 October 2023
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Abstract
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.Keywords
Funding Information
- National Institutes of Health (P30 CA008748, R37CA259260)
- National Cancer Institute (P30 CA008748, R37CA259260)
This publication has 27 references indexed in Scilit:
- The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman DiseaseMayo Clinic Proceedings, 2019
- Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman diseaseHaematologica, 2019
- Efficacy of MEK inhibition in patients with histiocytic neoplasmsNature, 2019
- Cobimetinib (GDC-0973, XL518)2018
- Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes diseaseBlood, 2018
- Phenotypes and survival in Erdheim‐Chester disease: Results from a 165‐patient cohortAmerican Journal of Hematology, 2018
- Cutaneous manifestations of paediatric Erdheim-Chester disease, a histiocytosis of the 'L' groupBritish Journal of Dermatology, 2018
- The histopathology of Erdheim–Chester disease: a comprehensive review of a molecularly characterized cohortLaboratory Investigation, 2017
- Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)Blood, 2017
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesBlood, 2016